The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs

The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs

Abstract Background Treatment with disease-modifying anti-rheumatic drugs (DMARDs) has raised concerns about the risk of malignancies in rheumatoid arthritis (RA) patients. However, the association between biologic DMARDs (bDMARDs) and malignancy in previous reports remains controversial. Therefore...

Full description

Bibliographic Details
Main Authors: Soo-Kyung Cho, Jiyoung Lee, Minkyung Han, Sang-Cheol Bae, Yoon-Kyoung Sung
Format: Article
Language:English
Published: BMC 2017-12-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Malignancies
Disease-modifying anti-rheumatic drugs
Biologic DMARDs
Online Access:http://link.springer.com/article/10.1186/s13075-017-1482-y

Internet

http://link.springer.com/article/10.1186/s13075-017-1482-y

Similar Items